Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
University of Maryland, Baltimore
Study ID
NCT00015951
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • cytarabine — DRUG
  • mitoxantrone hydrochloride — DRUG

Study Details

RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.

Key Dates

First listed
Jan 27, 2003
Start date
Apr 30, 2001
Status verified
Oct 2019
Primary completion
Apr 30, 2003
Completion
Mar 31, 2004

Study Design

Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Blood and Marrow Transplant Group of GeorgiaAtlantaGeorgia30342-1601-
Marlene and Stewart Greenebaum Cancer Center, University of MarylandBaltimoreMaryland21201-
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-

Find similar trials in Atlanta, GA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Blood and Marrow Transplant Group of Georgia· Atlanta, GAMarlene and Stewart Greenebaum Cancer Center, University of Maryland· Baltimore, MDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies